|
|
 |
|
Viewing report
|
|
|
|
Premium Company Profile Aspreva Pharmaceuticals Corporation
Datamonitor, Nov 2007, Pages: 39
Introduction
Aspreva is a pharmaceutical company involved in identifying, developing and commercializing drugs and drug candidates for the treatment of less common diseases. Aspreva has worldwide rights, excluding Japan, to develop and commercialize Roches CellCept (mycophenolate mofetil) for all autoimmune indications.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
Aspreva is focused on the development and commercialization of CellCept for autoimmune indications. The company develops CellCept for the indications such as Lupus nephritis, multiple sclerosis, pemphigus vulgaris, and scleroderma/systemic sclerosis. CellCept is under various stages of drug development process for the above said indications. Aspreva derives its revenues from royalties received from its collaborative agreement with Roche. The company started recording revenues from fiscal 2005 only. Its total revenues increased from $76 million in 2005 and $215 million in 2006, representing an absolute total growth of +$139 million during 2005-2006. The company is forecast to derive all of its revenues from CellCept royalties. The companys revenues are forecast to grow at a CAGR of 9% during 2006-2010, from $215 million to $304 million 2010. This represents an absolute growth of +$89 million.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand companys strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to companys adjusted five year financial data along with key ratios and market capitalization
Customers who bought this item also bought
Autoimmune Market Forecast to 2014
Aspreva Pharmaceuticals Corporation-Financial Company Report
Aspreva Pharmaceuticals Corp (ASPV) 2005 Annual Report
Autoimmune Treatment (2009 - 2014)
Hematological Malignancies: Companies Target Niche Indications to Facilitate Market Entry
Pipeline Insight: Multiple Sclerosis - The Oral Revolution
Aspreva Pharmaceuticals Corporation-Therapeutic Competitors
Lifestyle Drugs Market Outlook: Key Indications, Epidemiology, and Emergent Drugs
The Autoimmune Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Amyotrophic Lateral Sclerosis: Strategies for Drug Developers
Commercial Insight: Autoimmune Overview - Market continues to prosper
Acquisition of Aspreva Pharmaceuticals Corporation by Galenica Group Call - Aspreva Pharmaceuticals Corp. - Earnings Transcript
|
|
|
|
